Roche Diabetes Care at ATTD 2020

February 19 – 22, 2020, in Madrid, Spain

Order publications and solutions brochures

Exhibit Info

Exhibit Info

We look forward to welcoming you to the Roche Diabetes Care exhibition booth! Find out more on integrated personalized diabetes management at the Roche Diabetes Care booth.

Conference Location:

IFEMA Palacio Municipal

Campo de las Naciones

Av. de Capital Espana 7

28042 Madrid, Spain

Exhibition:

Exhibition Hall, floor 3


Booth number:

24

Opening hours:

Wednesday, February 19: 19:00 – 21:00

Thursday, February 20: 9:30 – 15:30

Friday, February 21: 9:30 – 15:30

Saturday, February 22: 9:30 – 12:00

Location map:

Roche Diabetes Care Symposium

integrated Personalised Diabetes Management: United we manage diabetes better

Friday, 21 February 2020
Time: 10.30 – 12.00

IFEMA Palacio Municipal Auditorium A

Chairs: María Asunción Martínez-Brocca (Spain), Rolf Hinzmann (Roche Diabetes Care, Germany)

Speaker

Optimising therapy with an open ecosystem: United we manage diabetes better

Julien Boisdron

Roche Diabetes Care

Basel, Switzerland

Improving patients‘ and health-economic outcomes with integrated Personalised Diabetes Management

Wendelin Schramm

Heilbronn University

Heilbronn, Germany

Insulin delivery today and in the future – Opportunities and challenges

Nick Oliver

Imperial College London

United Kingdom

Abstracts & Posters

Insulin delivery with patch pumps - Basal rate accuracy

Insulin delivery with patch pumps – Basal rate accuracy

  • E-Poster Viewing, E-Poster Area

  • Author: Waldenmaier D. et al.

Accuracy of insulin delivery in durable pumps

Accuracy of insulin delivery in durable pumps

  • E-Poster Viewing, E-Poster Area

  • Author: Ziegler R. et al.

Occlusion detection time in patch pumps

Occlusion detection time in patch pumps

  • E-Poster Viewing, E-Poster Area

  • Author: Waldenmaier D. et al.

Receive Roche Diabetes Care solutions brochures and publications via email!

Order now

Publications:

Use of an Insulin Bolus Advisor Improves Glycemic Control in Multiple Daily Insulin Injection (MDI) Therapy Patients With Suboptimal Glycemic Control: First results from the ABACUS trial
(Ziegler et al. Diabetes Care. 2013 Nov;36(11):3613-9.)
Use of an Automated Bolus Calculator in MDI-Treated Type 1 Diabetes - The BolusCal Study, a randomized controlled pilot study
(Schmidt et al. Diabetes Care. 2012 May;35(5):984-90.)
System Accuracy Evaluation of 43 Blood Glucose Monitoring Systems for Self-Monitoring of Blood Glucose According to DIN EN ISO 15197
(Freckmann et al. J Diabetes Sci Technol. 2012 Sep 1;6(5):1060-75.)
Evaluation of a new digital automated glycemic pattern detection tool
(Comellas et al. Diabetes Technol Ther. 2017 Nov 1; 19(11): 633–40.)
Use of Diabetes Data Management Software Reports by Health Care Providers, Patients With Diabetes, and Caregivers Improves Accuracy and Efficiency of Data Analysis and Interpretation Compared With Traditional Logbook Data: First Results of the Accu-Chek Connect Reports Utility and Efficiency Study (ACCRUES)
(Hinnen et al. J Diabetes Sci Technol. 2015 Mar;9(2):293-301.)
What Do We Need beyond Hemoglobin A1c to Get the Complete Picture of glycemia in people with diabetes?
(Hinzmann et al. Int J Med Sci. 2012;9(8):665-81)
Benefits and limitations of MARD as a performance parameter for continuous glucose monitoring in the interstitial space
(Heinemann et al. J Diabetes Sci Technol. 2020 Jan;14(1):135-150.)
A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II
(Christiansen et al. Diabetes Technol Ther. 2018 Jan 30 (Epub))
Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial
(Kropff et al. Diabetes Care. 2017 Jan;40(1):63-68.)
Utilizing the ambulatory glucose profile to standardize and implement continuous glucose monitoring in clinical practice
(Johnson et al. J Diabetes Sci Technol. 2019 Jun;21(S2):S217-S225.)
Concept and implementation of a novel patch pump for insulin delivery
(Ulbrich et al. J Diabetes Sci Technol. 2019 Aug [epub])
Comparative handling analysis of different insulin pump systems
(Waldenmaier et al. J Diabetes Sci Technol. 2018 Mar; 12(2):401–406.)
Accuracy of bolus and basal rate delivery of different insulin pump systems
(Freckmann et al. Diabetes Technol Ther. 2019 Apr;21(4):201-208.)
Using insulin pump with a remote-control system in young patients with diabetes improves glycemic control and enhances patient satisfaction
(Deeb et al. Clin Diabetes Endocrinol. 2019 Jun 6;5:7.)
Accuracy assessment of bolus and basal rate delivery of different insulin pump systems used in insulin pump therapy of children and adolescents.
(Ziegler et al. Pediatr Diabetes. 2020 Jan [epub])
A New Optimized Percutaneous Access System for CIPII
(Garcia-Verdugo et al. J Diabetes Sci Technol. 2017 Jul;11(4):814-821.)
Continuous subcutaneous insulin infusion: Special needs for children
(Adolfsson et al. Pediatr Diabetes. 2017 Jun;18(4):255-261)
Occlusion detection time in insulin pumps at two different basal rates
(Freckmann et al. J Diabetes Sci Technol 2018 ;12(3):608–613)
Establishing methods to determine clinically relevant bolus and basal rate delivery accuracy of insulin pumps
(Kamecke et al. J Diabetes Sci Technol 2018; ePub)
Patch Pumps: Are They All the Same?
(Heinemann et al. J Diabetes Sci Technol. 2019 Jan;13(1):34-40.)
Open Source Closed-Loop Insulin Delivery Systems: A Clash of Cultures or Merging of Diverse Approaches?
(Barnard et al. J Diabetes Sci Technol. 2018 Nov;12(6):1223-1226)
Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18 168 people with type 1 diabetes: observational study
(Steineck et al. BMJ 2015; 350: h3234.)
Boluses in insulin therapy
(Ziegler et al. J Diabetes Sci Technol 2017; 11(1):165-71.)
Virtual coaching to enhance diabetes care
(Ramchandani et al. Diabetes Technol Ther. 2019 Jun;21(S2):S248-S251.)
Use of telemedicine technologies in diabetes prevention and control in resource-constrained settings - lessons learned from emerging economies
(Pradeepa et al. Diabetes Technol Ther. 2019 Jun;21(S2):S29-S216.)
Current status and future directions for electronic point-of-care clinical decision support
(O’Connor et al. Diabetes Technol Ther. 2019 Jun;21(S2):S226-S234.)
The emerging role of telemedicine and mobile health technologies in improving diabetes care
(Garg et al. Diabetes Technol Ther. 2019 Jun;21(S2):S21-S23.)
Use of artificial intelligence to improve diabetes outcomes in patients using multiple daily injections therapy
(Forlenza et al. Diabetes Technol Ther. 2019 Jun;21(S2):S24-S28.)
Real-world assessments of mySugr mobile health app
(Debong et al. Diabetes Technol Ther. 2019 Jun;21(S2):S235-S240.)
A digital-first model of diabetes care
(Cafazzo et al. Diabetes Technol Ther. 2019 Jun;21(S2):S252-S258.)
Utilizing eHealth and telemedicine technologies to enhance access and quality
(Barnard et al. Diabetes Technol Ther. 2019 Jun;21(S2):S241-S247.)
Use of a Novel, Remotely Connected Diabetes Management System Is Associated with Increased Treatment Satisfaction, Reduced Diabetes Distress, and Improved Glycemic Control in Individuals with Insulin-Treated Diabetes: First Results from the Personal Diabe-tes Management Study
(Mora et al. Diabetes Technol Ther. 2017 Dec 1; 19(12): 715–22.)
Patient-centred care in type 2 diabetes mellitus - key aspects of PDM-ProValue are reflected in the 2018 ADA/EASD consensus report.
(Patient-centred care in type 2 diabetes mellitus - key aspects of PDM-ProValue are reflected in the 2018 ADA/EASD consensus report.)
Benefit of digital tools used for Integrated Personalized Diabetes Management: results from the PDM-ProValue Study Program.
(Heinemann et al. J Diabetes Sci Technol. 2019 Aug [epub])
Integrated Personalized Diabetes Management (PDM): Design of the ProValue Stud-ies: Prospective, Cluster-Randomized, Controlled, Intervention Trials for Evaluation of the Effectiveness and Benefit of PDM in Patients With Insulin-Treated Type 2 Diabe-tes.
(Kulzer et al. J Diabetes Sci Technol. 2016 May 3;10(3):772-81.)
Integrated personalized diabetes management improves glycemic control in patients with insulin-treated type 2 diabetes: Results of the PDM-ProValue study program
(Kulzer et al. Diab Res Clin Pract. 2018 Oct;144:200-212)
PDM-ProValue meets cardiovascular outcome trials in diabetes
(Fritzen et al. Cardiovasc Diabetol. 2019 Jan 28;18(1):10)
Predicting the early risk of chronic kidney disease in patients with diabetes using real-world data
(Freckmann et al. J Diabetes Sci Technol 2018 ;12(3):608–613)
Modeling of Diabetes and Its Clinical Impact
(Fritzen et al. J Diabetes Sci Technol. 2018 Sep;12(5):976-984.)
New design of a percutaneous port system for continuous intraperitoneal insulin infusion
(Rieger et al. J Diabetes Sci Technol. 2019 Nov;13(6):1158-1160.)
Continuous intraperitoneal insulin infusion: an alternative route for insulin delivery in type 1 diabetes.
(Pasquini et al. Acta Diabetol. 2020 Jan;57(1):101-104.)
Intraperitoneal insulin delivery provides superior glycaemic regulation to subcutaneous insulin delivery in model predictive control-based fully-automated artificial pancreas in patients with type 1 diabetes: a pilot study.
(Dassau et al. Diabetes Obes Metab. 2017 Dec;19(12):1698-1705.)
Outpatient closed-loop control with unannounced moderate exercise in adolescents using zone model predictive control
(Huyett et al. Diabetes Technol Ther. 2017 Jun 1; 19(6): 331–339.)
Day-and-night closed-loop control using the unified safety system in adolescents with type 1 diabetes at camp.
(Ly et al. Diabetes Care. 2016 Aug;39(8):e106-7.)
Artificial pancreas: clinical study in latin america without premeal insulin boluses.
(Sanchez-Pena et al. J Diabetes Sci Technol. 2018 Sep;12(5):914-925.)
Closed-loop control without meal announcement in type 1 diabetes.
(Cameron et al. Diabetes Technol Ther. 2017 Sep;19(9):527-532.)
Overnight closed-loop control improves glycemic control in a multicenter study of adults with type 1 diabetes
(Brown et al. Clin Endocrinol Metab. 2017 Oct 1;102(10):3674-3682.)
Closed-loop control during intense prolonged outdoor exercise in adolescents with type 1 diabetes: the artificial pancreas ski study.
(Breton et al. Diabetes Care. 2017 Dec;40(12):1644-1650.)
Twelve-week 24/7 ambulatory artificial pancreas with weekly adaptation of insulin delivery settings: effect on hemoglobin a1c and hypoglycemia.
(Dassau et al. Diabetes Care. 2017 Dec;40(12):1719-1726.)

Brochures - Our Solutions:

Accu-Chek® Solo

  • First detachable and tube-free insulin pump
  • Unique quick bolus buttons on pump
  • Diabetes Manager with open bolus advice to combine therapy with continuous glucose monitoring solutions

mySugr

  • Quick, automated, easy-to-understand logging of BG levels, via Bluetooth
  • Automatic data integration of leading BG meters (e.g. Accu-Chek Guide), CGM devices (e.g. Eversense), as well as cloud-based integrations (Apple Health, Google Fit) ; Future integration of Novo Nordisk smart insulin pens
  • Bolus calculator
  • Easy-to-read reports
  • More than 2 million registered users

Eversense® XL

  • Up to 6 months wearing time
  • Removable smart transmitter with on-body vibe alerts
  • Predictive alerts before reaching low or high glucose level
  • Simple, 5-minute in-office insertion
  • Wireless data connection to mySugr

RocheDiabetes Care Platform

  • Provides quick insights to identify patterns and trends to support clinical decision making
  • Simple reports facilitate communication to help support patient-learning and engagement
  • Open connectivity to 130+ devices to increase patient insights and simplify workflow, including smart insulin pens (Novo Nordisk smart pens)

Accu-Chek® SugarView

  • All you need is a smartphone, an Accu-Chek Active blood glucose test strip, a lancet, and the app to see your blood glucose test range and know what to do next.
  • Feel motivated and assured about your type 2 diabetes as you know your next step.
  • Know how you are doing in between your doctor’s appointments in an affordable way.

RocheDiabetes InsulinStart

  • Guided process that provides clear, actionable advice to the person with diabetes, for a safe and effective start at insulin therapy
  • Proven algorithms help people with diabetes find their optimum insulin dosage
  • Add-on to the Accu-Chek Smart Pix software

Accu-Chek® Guide

  • Easy-to-remove test strips with spill-resistant SmartPack vial
  • Strip port light, wide, easy-edge test strip, and meter strip ejection
  • Wireless transmission of results to mySugr app

Accu-Chek® Smart Pix

  • Open version allows for read-out of devices from Roche and other manufacturers
  • All data seamlessly available in one system
  • Easy and fast conclusions and therapy adaptations possible
  • asily understandable visualisation of different diabetes-relevant data

Accu-Chek® Insight

  • Intuitive & discreet: Diabetes manager with full remote control with bolus advice, and accurate insulin delivery
  • Easy & safe: Pre-filled cartridges (Novo Rapid PumpCart) for reduced patient effort and minimised risk of air bubbles

Accu-Chek® Instant

  • Target Range Indicator – For instant clarity on results
  • Easy navigation – Only 1 button needed!
  • Easy-edge dosing – Wide blood application area compared to leading brands
  • Connection to mySugr app – No more manual diaries